Tests possible cancer drugs on mouse tumors grown from patients' own samples
Grows tumors from patients with breast, colon or ovarian cancer in mice to test drugs.
Plain-language title generated from the registry record
Registry title: Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with triple negative breast cancer, colorectal cancer, high grade serous ovarian cancer, or another solid tumor, whose tumor tissue can be taken for testing in mice.
- Age
- Over 18 years.
- Sex
- All sexes can join.
- Disease stage
- Triple negative breast cancer: stage IV not yet treated with systemic therapy for metastases, or stage I to III with leftover tumor after chemotherapy. Colorectal cancer: stage IV. Ovarian cancer: advanced high grade serous, recurrent or stage III or IV. Other solid tumors at the study doctor's discretion.
- Earlier treatment
- Triple negative breast cancer: stage IV disease with no systemic therapy for metastases, or stage I to III disease with leftover tumor after anthracycline + taxane-containing chemotherapy before surgery. Colorectal cancer: no more than 1 line of systemic therapy for metastases.
Main reasons for not taking part
- Serious liver, kidney, heart or other organ problems that could limit taking part in trials
- Known brain metastasis
- A condition that affects the ability to give consent, such as dementia or severe cognitive impairment
- Any reason that a biopsy cannot be done
- Tumor that cannot be reached by biopsy or surgery
Read by machine on 12 November 2026.
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaContact: Elizabeth ShahTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT02732860
- Record updated
- 4 May 2026
- Original description
By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment optionsRead full original descriptionShow less
Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host
By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options
Inclusion: Age > 18 years; Patient diagnosis must be categorized as either (I) OR (II) OR (III) OR (IV):; (I) Histologically confirmed Triple Negative Breast Cancer by Institutional and American Society of Clinical Oncology (ASCO)/Cancer of American Pathologists (CAP) guidelines, either:; Stage IV (metastatic) disease that has not been treated with systemic therapy in the metastatic setting or; Stage I to III (non-metastatic) with residual mass by clinical exam and/or breast imaging following anthracycline + taxane-containing neoadjuvant chemotherapy; OR; (II) Histologically-confirmed Stage IV colorectal cancer treated with ≤ 1 line of systemic therapy in the metastatic setting, either:; Undergoing surgical resection of liver metastases or; With metastatic lesions amenable to biopsy; OR; (III) Histologically-confirmed advanced High Grade Serous Ovarian Cancer, either:; Recurrent disease with a life expectancy of at least 12 months or; Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence; OR; (IV) Histologically confirmed solid tumor not meeting criteria for (I), (II) or (III) above, for which evaluation of investigational therapies is of particular interest or where clinical need exists, at the discretion of the PI; Disease amenable to biopsy or surgery for tissue procurement; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Willingness and ability of patient to provide signed voluntary informed consent.
Exclusion: Clinically significant hepatic, renal, cardiac or other organ dysfunction likely to limit participation in clinical trials; Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment; Known brain metastasis; Any contraindication to undergoing a biopsy procedure.